A tuberculosis (TB) vaccine candidate, Mtb72, was developed following an antigen discovery program involving a combination of expression cloning strategies and evaluation of human immune responses. Adjuvant selection was also performed, resulting in the prioritization of AS02A and AS01B, and an industrial process for vaccine production was developed. Safety, immunogenicity, and protection studies in mice, guinea pigs, rabbits, and monkeys supported the initiation of clinical development of Mtb72f in AS02A.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.micinf.2005.03.011 | DOI Listing |
Publication Analysis
Top Keywords
tuberculosis vaccine
8
vaccine development
4
development mouse
4
mouse man
4
man tuberculosis
4
vaccine candidate
4
candidate mtb72
4
mtb72 developed
4
developed antigen
4
antigen discovery
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!